< Back to previous page
Researcher
Nathalie Goemans
- Disciplines:Orthopaedics
Affiliations
- Locomotor and Neurological Disorders (Division)
Member
From1 Jan 2019 → Today - Woman and Child (Division)
Member
From1 Apr 2013 → 31 Dec 2018
Projects
1 - 6 of 6
- Improved understanding of gait compensations to explore new pathways of gait rehabilitation in growing children with Duchenne muscular dystrophyFrom1 Oct 2018 → TodayFunding: FWO fellowships
- Understanding and management of neurobehavioral difficulties in patients with Duchenne Muscular DystrophyFrom1 Oct 2018 → 1 Oct 2022Funding: Own budget, for example: patrimony, inscription fees, gifts
- Early developmental assessment in children with typical development and Duchenne Muscular DystrophyFrom1 Sep 2017 → 1 Sep 2021Funding: Own budget, for example: patrimony, inscription fees, gifts
- BIOIMAGE-Neuromuscular DiseasesFrom10 Dec 2013 → 31 Mar 2017Funding: General Activities (Annex IV)
- The underlying neuromuscular mechanisms contributing to muscle weakness and their interaction with gaitFrom1 May 2013 → 14 Sep 2018Funding: Own budget, for example: patrimony, inscription fees, gifts
- Evaluation of upper limb function in children and young men with Duchenne Muscular Dystrophy.From1 Nov 2012 → 31 Aug 2017Funding: Foreign private sponsor - undefined, Foreign foundations, funds with scientific view
Publications
1 - 10 of 161
- Reference curves of motor function outcomes in young steroid-naïve males with Duchenne muscular dystrophy(2024)
Authors: Jasmine Hoskens, Nathalie Goemans, Hilde Feys, Katrijn Klingels
- Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy: A Randomized Controlled Trial.(2024)
Authors: Nathalie Goemans, Liesbeth De Waele
Pages: e208112 - Comparison of two corticosteroid regimens on brain volumetrics in patients with Duchenne muscular dystrophy(2023)
Authors: Sam Geuens, Jeroen Van Dessel, Nathalie Goemans, Jurgen Lemiere, Liesbeth De Waele
Pages: 1 - 10 - Sunfish parts 1 and 2: 4-year efficacy and safety data of risdiplam in types 2 and 3 spinal muscular atrophy (SMA)(2023)
Authors: Nathalie Goemans
- 269th ENMC international workshop: 10 years of clinical trials in Duchenne muscular dystrophy - What have we learned? 9-11 December 2022, Hoofddorp, The Netherlands(2023)
Authors: Nathalie Goemans
Pages: 897 - 910 - The impact of clinical trial participation on quality of life and psychosocial well-being in children with Duchenne muscular dystrophy and their parents(2023)
Authors: Sam Geuens, Nathalie Goemans, Jurgen Lemiere, Liesbeth De Waele
Pages: 877 - 881 - Illness Perceptions and Illness Identity in Adolescents and Emerging Adults With Neuromuscular Disorders(2023)
Authors: Sam Geuens, Koen Raymaekers, Sofie Prikken, Nathalie Goemans, Liesbeth De Waele, Jurgen Lemiere, Koen Luyckx
Pages: 983 - 996 - Psychopharmaceutical treatment for neurobehavioral problems in Duchenne muscular dystrophy: a descriptive study using real-world data(2023)
Authors: Sam Geuens, Nathalie Goemans, Liesbeth De Waele
Pages: 619 - 626 - Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA)(2023)
Authors: Nathalie Goemans
Pages: 2531 - 2546 - Two-year efficacy and safety of risdiplam in patients with type 2 or non-ambulant type 3 spinal muscular atrophy (SMA) (vol 270, pg 2531, 2023)(2023)
Authors: Nathalie Goemans